Similarly, integrated transcriptomic–metabolomic analyses have uncovered cuproptosis-associated gene networks (e.g., FDX1, DLAT, LIAS) that correlate with immunotherapy outcomes in melanoma, lung cancer, and hepatocellular carcinoma (81, 85–87). The gene discussed is FDX1; the disease is lung carcinoma.